Longeveron Inc. (LGVN): Price and Financial Metrics
LGVN Price/Volume Stats
| Current price | $0.52 | 52-week high | $4.40 |
| Prev. close | $0.52 | 52-week low | $0.42 |
| Day low | $0.49 | Volume | 150,000 |
| Day high | $0.54 | Avg. volume | 429,626 |
| 50-day MA | $1.35 | Dividend yield | N/A |
| 200-day MA | $2.40 | Market Cap | 12.25M |
LGVN Stock Price Chart Interactive Chart >
LGVN POWR Grades
- Sentiment is the dimension where LGVN ranks best; there it ranks ahead of 73.43% of US stocks.
- The strongest trend for LGVN is in Growth, which has been heading up over the past 107 days.
- LGVN's current lowest rank is in the Quality metric (where it is better than 3.88% of US stocks).
LGVN Stock Summary
- LONGEVERON INC's stock had its IPO on February 12, 2021, making it an older stock than just 9.58% of US equities in our set.
- LGVN's price/sales ratio is 39.95; that's higher than the P/S ratio of 96.11% of US stocks.
- As for revenue growth, note that LGVN's revenue has grown -41.45% over the past 12 months; that beats the revenue growth of merely 6.26% of US companies in our set.
- Stocks that are quantitatively similar to LGVN, based on their financial statements, market capitalization, and price volatility, are ONVO, WATT, ASXC, LCTX, and AKTS.
- To check out LONGEVERON INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001721484.
LGVN Valuation Summary
- LGVN's price/earnings ratio is -1.6; this is 105.49% lower than that of the median Healthcare stock.
- Over the past 35 months, LGVN's price/earnings ratio has gone up 40.6.
Below are key valuation metrics over time for LGVN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LGVN | 2023-12-29 | 42.1 | 4.9 | -1.6 | -1.6 |
| LGVN | 2023-12-28 | 43.0 | 5.0 | -1.6 | -1.6 |
| LGVN | 2023-12-27 | 43.0 | 5.0 | -1.6 | -1.6 |
| LGVN | 2023-12-26 | 45.2 | 5.2 | -1.7 | -1.7 |
| LGVN | 2023-12-22 | 41.5 | 4.8 | -1.5 | -1.6 |
| LGVN | 2023-12-21 | 38.7 | 4.5 | -1.4 | -1.4 |
Longeveron Inc. (LGVN) Company Bio
Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers in October 9, 2014 and is headquartered in Miami, FL.
Latest LGVN News From Around the Web
Below are the latest news stories about LONGEVERON INC that investors may wish to consider to help them evaluate LGVN as an investment opportunity.
Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMIAMI, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,355,301 shares of its |
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.74 |
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.62 |
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s DiseaseNew clinical data showed that Lomecel-B™ improved cognitive function in multiple measures in a dose-response fashion Caregiver ratings documented improved quality of life in Lomecel-B™ treated patientsMRI Biomarker study data showed that Lomecel-B™ countered loss of brain volume in multiple areas associated with Alzheimer’s disease, reduced brain neuroinflammation and improved cerebral blood flow Overall results confirmed the drug product’s therapeutic potential in the treatment of mild Alzheime |
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa’el Hashad, CEO of Longeveron Inc.LOS ANGELES, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bel |
LGVN Price Returns
| 1-mo | -58.73% |
| 3-mo | -71.43% |
| 6-mo | -84.10% |
| 1-year | -86.21% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -61.76% |
| 2023 | -57.76% |
| 2022 | -73.32% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...